Skip to main content
OpenTrials
Completed

NCT Number: NCT04157829

Evaluation of the Performance and Safety of a Medical Device Developed to Improve the Reading of Dyslexic Patients

The aim of this study is to evaluate the efficacy and safety of a new medical device on the improvement of reading skills of dyslexic patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year–11 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Dr Laurence Derieux, Caen, France

Loading trial locations.

About this study

Dyslexia is defined as a specific learning disability that is characterized by reading difficulties, in the absence of intellectual disability, neurological or psychiatric disorder, uncorrected sensory disturbance (sight, hearing) or an educational deficiency.

Dyslexia appears in the child from the earliest stages of learning in the form of a difficulty in mastering the learning of reading. This disorder is manifested by a generally hesitant reading, slowed down, full of errors, requiring a lot of effort for the child and may impact his reading comprehension. The dyslexia-related deficiency is of variable intensity depending on the individual; it may be accompanied by calculus disorders (dyscalculia), oral language (dysphasia), motor coordination (dyspraxia) or attention disorders with or without hyperactivity. In nearly 40% of cases, a child affected by Dys disorders presents several learning disorders.

To date, the causes of dyslexia are not yet clearly established. The wide variety of symptoms and disorders associated with dyslexia does not facilitate the identification of precise neurobiological / psycho cognitive mechanisms. There are therefore several theories: phonological, visual, temporal, cerebellar or proprioceptive auditory processing.

Recently, following work published in 2017, an anatomical cause based on Maxwell's spots could also be a cause of dyslexia.

The aim of this study is to evaluate a new medical device to compensate this probable anatomical cause.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Schooled in CE2, CM1 or CM2,
  • French mother tongue,
  • For whom developmental dyslexia has been diagnosed by a health professional who specializes in this learning disorder,
  • Presenting an IQ ≥ 80 and ≤130 according to the WISC-V test performed by a psychologist,
  • For which a written consent was obtained regarding his study participation.

Exclusion criteria

  • With medical history or presenting a neurological pathology,
  • Presenting a developmental disorder (autism, ADHD, ...),
  • Presenting hearing disorders,
  • Presenting visual disorders,
  • Any other condition that, in the opinion of health professionals, could impair its ability to complete the study or could pose a significant risk.

Treatment and study plan

Scintilling lamp

Device

Lamp with a standardized scintilling

Classic lamp

Device

Lamp without a scintilling

Primary outcomes

  1. Reading performance aloud of a text with french E.L.FE Test

    Time frame: 1 day

    E.L.FE Test (=Evaluation de la Lecture en FluencE) - "Monsieur Petit" and "Le Géant égoïste" texts : percentile

Secondary outcomes

  1. Reading performance aloud of isolated words with french BALE Test

    Time frame: 1 day

    BALE test (=Batterie Analytique de Langage Ecrit): percentile

  2. Security: incidence of Adverse Events

    Time frame: 1 day

    By questioning the patient & the speech therapist - evaluation of adverse effects due to scintilling lamp (Yes/ No): headache, nausea, dizziness, fatigue and eye fatigue. Accotding to patient questioning and clinical exam, the Adverse Event Table will be completed (description, dates, severity, imputability, action,...).

  3. Patient's satisfaction regarding reading fluency

    Time frame: 1 day

    patient interview with VAS (Visual Analogue Scale): 0 - 100 mm

  4. Speech therapist's satisfaction regarding Securirty, Performance and usability of scintilling lamp

    Time frame: 1 day

    speech therapist interview with 4 points - Likert scale (Very good, Good, Moderate, Bad)

Sponsors and collaborators

Lead sponsor

SATT Ouest Valorisation

Other

Collaborators

  • Slb Pharma

Registry information

Official study title

Evaluation of the Performance and Safety of a Scintillating Lamp Developed to Improve the Reading of Dyslexic Patients

Acronym: DysLight

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Nov 8, 2019
Registry last updated
Apr 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.